Company News for Jun 7, 2021

Zacks Equity Research Published on June 07, 2021

Shares of Regeneron Pharmaceuticals, Inc. (REGN - Free Report) rose 1.2% after the company reported that US regulators had authorized a lower-dose and subcutaneous version of its COVID-19 antibody treatment.
Coherus BioSciences, Inc.’s (CHRS - Free Report) shares jumped 1.8% after the company and Junshi Bio jointly disclosed that toripalimab in combination with chemo met primary endpoint as the first-line treatment of metastatic nasopharyngeal carcinoma.
Shares of Senseonics Holdings, Inc. (SENS - Free Report) surged nearly 42% after the company reported results from a study evaluating its Eversense CGM System for up to 180 days.
Cullinan Oncology, Inc.’s (CGEM - Free Report) shares jumped 11.3% after the company disclosed Phase 1/2a interim data for its Cullinan Pearl's CLN-081 on 20 patients.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.